AG Magazine • Health & Nutrition
For decades, creatine research meant young men in weight rooms. That changed this autumn. In the space of five weeks, two randomized trials run only in women landed in print — one testing thinking skills in younger and older women, one testing sleep and menopause symptoms in perimenopausal women who lift. They join a 2026 pooled analysis of every placebo-controlled trial in postmenopausal women. So the question “does creatine work for women?” finally has women-specific answers — and they are more specific, and more conditional, than the marketing version.
Creatine monohydrate is a compound your body makes from amino acids and that you also eat in meat and fish. It is stored mostly in muscle as phosphocreatine, a rapid-recharge battery for short, hard effort, and the brain uses the same energy system. What the trials below support is a short list: a modest muscle and strength benefit when it is paired with resistance training, an early and unconfirmed signal for memory and sleep consistency, and no support — so far — for the bone-density claim doing the rounds. Here is each claim next to the study it rests on.
Get more like this — weekly.
One email a week. Research-backed wellness, translated into things you can actually do. No spam.
Why Women Start From a Different Baseline
The women-specific research starts from a measurable difference. According to a 2021 lifespan review in the journal Nutrients, females carry roughly 70–80% lower endogenous creatine stores than males, eat less dietary creatine on average, and experience hormone-related shifts in creatine metabolism across the menstrual cycle, pregnancy, and the menopause transition. Estrogen influences the enzymes involved, which is one reason researchers who study women specifically argue the supplement may matter more, not less, at midlife — and why borrowing conclusions from trials in 22-year-old men is not good enough.
That review also sets the honest frame for everything that follows: the performance evidence in pre-menopausal women is reasonably consistent, the postmenopausal evidence is newer and thinner, and the mood and cognition findings are signals that still need confirmatory trials.
Muscle and Strength: The Strongest Case — and It Needs a Barbell
What did the 2026 postmenopausal meta-analysis actually find?
A 2026 systematic review and meta-analysis in the Journal of the International Society of Sports Nutrition pooled the seven randomized, placebo-controlled trials of creatine in postmenopausal women: 608 women, average age about 62, followed for 12 to 104 weeks. The pooled result was real but modest — lean mass up by an average of 0.37 kg versus placebo, and leg-press strength up by about 7.5 kg. Two conditions mattered. The benefits showed up when the dose was at least 5 grams a day and the women were resistance training. Trials using 3 grams a day or less without training showed no measurable effect.
The individual trials agree. In a 12-month Canadian trial published in Medicine & Science in Sports & Exercise, postmenopausal women who lifted three days a week gained substantially more relative bench-press strength on creatine than on placebo (64% versus 34%). And in our coverage of the Texas A&M trial on creatine without the gym, the pattern was the same in a mixed group aged 45 to 65: creatine helped, training helped more, and the combination beat both.
What happens if you take it without training?
The cleanest test is a two-year Brazilian trial in the Journals of Gerontology: 200 postmenopausal women with osteopenia took 3 grams a day or a placebo for two full years, with no structured training program. Creatine added nothing — no extra lean mass, no better muscle function, no bone benefit. On its own, at the standard dose, the powder is not the intervention. The training is; creatine is a small multiplier on top of it.
One more caveat on the pooled numbers: the 2026 meta-analysis was not registered in advance, and most of its seven trials carried at least “some concerns” on risk of bias. Treat +0.37 kg as a fair central estimate, not a promise.
Bone: The Claim the Long Trials Do Not Support
Bone density is the claim most often used to sell creatine to women after menopause, and it is the weakest one in the file.
- The early positive signal: In the 2015 Canadian trial above, the creatine group lost femoral-neck bone density more slowly over 12 months (−1.2% versus −3.9% on placebo) while lifting. Promising — but only 33 women finished that analysis, and one year is short for bone.
- The bigger, longer test: The same research group then ran a two-year trial in 237 postmenopausal women, all resistance training and walking, at a higher weight-based dose. Bone mineral density did not differ between creatine and placebo at any site. What creatine did preserve was some measures of hip bone geometry — the shape properties linked to bending strength — and the creatine group walked 80 metres slightly faster.
- The no-training test: In the two-year Brazilian trial, bone density, bone markers, and falls and fractures were all unchanged on creatine.
The 2026 meta-analysis lands in the same place: bone density unchanged overall. Preserving bone geometry in one trial is a genuine finding worth more research, but no trial has shown creatine preventing fractures, and it is not a treatment for low bone density. If bone is your reason for considering it, the lifting is doing the heavy lifting — creatine’s bone case is unproven.
Brain: A Women-Only Trial, and a Small Memory Signal
What did the November 2026 cognition trial in women find?
A randomized trial published online on November 2, 2026, in Biological Research for Nursing gave 48 active women — 26 younger, 22 older — either 3 grams of creatine a day or a placebo for 28 days, with a battery of thinking tests before and after. Compared with placebo, the creatine groups improved on several measures, most consistently reaction time to visual and sound cues, inhibitory control (staying on task despite distractions), and working memory. The statistical evidence was strongest in the older women.
The authors are careful, and so are we: they describe the study as exploratory, it ran many tests over just four weeks in 48 people, and they state plainly that the findings warrant confirmation in trials designed to test one specific question. It does not show that creatine prevents memory loss or dementia.
What do the pooled cognition trials say?
The women-only result fits the wider pattern. A 2024 meta-analysis in Frontiers in Nutrition pooled 16 randomized trials with 492 adults and found a small improvement in memory (standardized mean difference 0.31), rated moderate certainty, with weaker, low-certainty signals for attention and processing speed — and no significant effect on overall cognitive function or executive function. An earlier 2023 meta-analysis in Nutrition Reviews found the memory effect concentrated in adults aged 66 to 76 and essentially zero in younger adults — but that older-adult estimate rests on two small trials, and after a published statistical critique and re-analysis, the overall memory effect held up only in the older group. In the perimenopause trial covered next, creatine did not beat placebo on the thinking test itself; a brain-oxygenation measure moved, which is a mechanism clue, not a cognitive benefit.
The fair summary: a small, real-looking memory signal, clearest in older adults, from small short trials. Promising — not proven.
Sleep: The Perimenopause Finding Everyone Is Quoting
What did the October 2026 perimenopause trial measure?
A randomized trial published online on October 24, 2026, in the European Journal of Applied Physiology followed 51 perimenopausal women (average age 46) for six weeks. Eighteen took creatine alongside twice-weekly high-intensity resistance training, 20 took a placebo with the same training, and 13 were a non-training control group. The creatine group loaded at 20 grams a day for five days, then took about 4.5 grams a day. Sleep was tracked daily with a WHOOP wristband.
The headline result: at week six, sleep consistency — how regular the women’s sleep and wake times were — was 7.4 percentage points higher in the creatine group than the placebo group (p = 0.015), because the creatine group’s timing held steady while the placebo group’s drifted under the new training load. The creatine group also reported fewer days of temperature sensitivity, a menopause symptom category. Reaction time improved in both training groups equally — that was the training, not the creatine.
Three honest qualifiers. First, consistency is not quality or quantity: the trial did not show the women sleeping longer or waking less, and consistency matters in its own right — our breakdown of sleep regularity versus duration covers why regular timing predicts heart outcomes — but it is a narrower claim than “creatine improves sleep.” Second, the authors label the analysis exploratory, the groups were small, and the sleep result comes from the trained women only. Third, the trial’s funding included creatine manufacturers and the wearable company whose device measured the sleep — disclosed here because it is exactly the kind of thing we flag in other people’s studies.
Mood: Early Signals Only
The lifespan review notes positive early signals for creatine on mood, plausibly by supporting brain energy metabolism, and small trials in depression are an active research area — we covered that evidence separately in our creatine-and-depression breakdown. For this article’s purposes: mood is a reason researchers are interested, not a reason to start. Nothing in the women-specific trials above tested mood as a primary outcome, and creatine is not a treatment for depression.
How to Take It: Dose, Loading and Form
- Form first: Creatine monohydrate is the form used in essentially every trial cited here. More expensive forms — hydrochloride, buffered, gummies — have not shown superiority, and the women-specific evidence does not rest on them.
- Dose: 3–5 grams a day is the studied maintenance range. Note that the postmenopausal muscle benefit appeared at 5 grams a day or more with training; some bone-protocol trials used weight-based doses around 0.1 g per kilogram of body weight a day (roughly 7 grams for a 70 kg woman) — higher than a standard scoop, and still without a bone-density result.
- Loading is optional: A 20-gram-a-day loading week saturates muscle stores in days; the same saturation arrives in about four weeks on 3–5 grams a day. The perimenopause trial loaded; the cognition trial did not, and still found its effects at 3 grams. Skipping the load also skips most of the stomach upset and early scale jump.
- Timing barely matters: Consistency beats timing. Take it whenever you will actually take it daily, with food if it bothers your stomach.
- Expect water, not fat: Any early weight change is water drawn into muscle cells, typically a kilogram or so in the first weeks if you load — covered in the safety section below.
⚡ PRO TIP: Skip the loading phase and split the difference the trials actually support — 5 grams of plain creatine monohydrate once a day, stirred into something you already drink, paired with at least two resistance-training sessions a week. That is the exact combination behind the postmenopausal muscle result: at least 5 grams, plus lifting. A scoop without the training tested no better than placebo over two full years.
The Safety Questions, Answered One by One
Does creatine damage kidneys?
This is the claim we put to three AI chatbots in our first AG Evidence Audit, because the chatbots kept getting it half-wrong. The trial record: a 2025 analysis of 685 creatine clinical trials — 12,839 people on creatine, 13,452 on placebo, some studies running up to 14 years — found side effects in 4.60% of creatine participants versus 4.21% on placebo, no significant difference, and the postmenopausal meta-analysis found kidney indices unchanged. The kernel of truth in the myth: creatine raises creatinine, a routine lab marker, because creatine breaks down into creatinine — so a blood test can look like reduced kidney function in a healthy person. Tell your clinician you take it before blood work. (One disclosure on the 685-trial analysis: its publication was supported by a creatine manufacturer — the numbers are the numbers, but you should know who paid for the counting.) None of this covers people with existing kidney disease, who were largely excluded from the trials.
Does creatine cause hair loss?
The entire claim traces to one 2009 study of 20 college rugby players, in which a loading phase raised DHT — a hormone linked to hair loss — by 56%. That study never measured hair, the DHT values stayed within the normal clinical range, and the result has never been replicated. The ISSN’s 2021 review of common creatine questions concludes the current evidence does not indicate creatine raises DHT or causes hair loss. It was also a study in young men; there is no women-specific hair evidence either way. Honest verdict: unproven, from a single small study, and the burden of the literature is against it.
What about bloating and stomach upset?
Gastrointestinal upset is the most commonly reported side effect in the trial record, and even it was not significantly more frequent than placebo per participant in the 685-trial analysis (5.51% versus 4.05%). The water creatine draws goes into muscle cells, not under the skin, so the “bloated” look is not what the physiology predicts; the real-world complaints cluster around large single doses and loading weeks. Splitting the dose, taking it with food, and skipping the load are the standard fixes. In the perimenopause trial, symptom days were tracked daily — worth knowing that the trial’s clearest symptom win was fewer temperature-sensitivity days, not a stomach result in either direction.
Who should talk to a clinician first?
- Anyone with kidney disease, a single kidney, or medication monitored through kidney labs — the safety data come from people with healthy kidneys.
- Anyone pregnant or breastfeeding — creatine in pregnancy is a research topic, not an established recommendation; the trial data are not there.
- Anyone under 18 — outside this article’s audience, but the women-specific trials are adult trials.
- Anyone managing a complex condition or several medications — supplements are not regulated like drugs, so choose a third-party-tested product and put it on your medication list.
The Bottom Line for Women After 40
Creatine for women is neither the miracle the marketing describes nor the gym-bro relic it used to be filed as. The women-specific trials support one claim solidly: 5 grams of creatine monohydrate a day, combined with resistance training, produces small but real gains in lean mass and strength after menopause — about 0.37 kg of lean mass and 7.5 kg on the leg press across the pooled trials. Two brand-new trials add early, genuinely interesting signals — better thinking-test performance in older women after 28 days at just 3 grams, and steadier sleep timing in perimenopausal women who lift — and both sets of authors say the same thing we do: these need bigger, confirmatory trials. The bone-density claim, by contrast, has now failed its two longest tests. If you lift, creatine monohydrate at 5 grams a day is a reasonable, well-studied addition; if you don’t lift yet, the training is the purchase that matters — start there, and let the powder be the small print.
Educational content, not medical advice.
See everything that passed our three tests: The AG Shortlist →




No one seems to have shared their thoughts on this topic yet
Leave a comment so your voice will be heard first.